Biomea Fusion Stock Is Trading Higher Today - Here's Why

Biomea Fusion Inc BMEA announced the presentation of new clinical data from the first two cohorts from the Phase 2 portion of its ongoing Phase 1/2 clinical study (COVALENT-111) of BMF-219 in type 2 diabetes patients.

Patients who received BMF-219 in Cohort 2 and 3 had a mean HbA1c reduction of 0.1% and 1.0%, respectively.

For Cohort 3 (100 mg BMF-219 QD without food for four weeks):

• 50% of patients (n=5/10) saw a continued improvement in HbA1c with a mean reduction in HbA1c of 1.49% at Week 12, compared to the mean reduction of 0.9% (an additional 62% HbA1c reduction).
• 60% (n=6/10) of patients achieved an HbA1c of 7% or below at the end of Week 12, compared to 30% (n=3/10) at the end of the dosing period (Week 4) and 10% (n=1/10) at the end of Week 1.
• As measured by CGM, 70% of patients maintained or improved time in range while off treatment.

For Cohort 2 (100 mg BMF-219 QD with food for 4 weeks):

• 50% of patients (n=5/10) showed a mean reduction in HbA1c of 0.94%, an additional 114% HbA1c reduction compared to the mean reduction of 0.44%.
• 10% of patients achieved an HbA1c of 7% or below, compared to 0% (n=0/10) at the end of the dosing period (Week 4) and 0% (n=0/10) at the end of Week 1.
• As measured by continuous glucose monitoring, 6 of 10 (60%) of patients maintained or improved time in range while off treatment.

In March, Biomea Fusion announced data from the initial cohorts of the ongoing Phase 2 study of BMF-219, demonstrating that 89% of patients achieved a reduction in A1c. 78% saw at least a 0.5% reduction, and 56% achieved at least a 1% reduction.

Price Action: BMEA shares are up 20.60 at $37 during the premarket session on the last check Monday.